By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed up the biomedical distributor Dateks to market its colorectal cancer test in Turkey.

Epigenomics said that Dateks will market the Epi proColon, a DNA methylation-based test that detects colorectal cancer in blood plasma by identifying the Septin 9 biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.